Abstract
Intimal hyperplasia (IH) is the primary cause of vein bypass graft failure. The smooth muscle cell (SMC) is a key element of IH as it phenotypically switches from a contractile to a synthetic state which can become pathological. R7020, which is an engineered strain of Herpes Simplex Virus-1, inhibits IH in animal models. Although it has many characteristics which make it a strong candidate for use as a prophylactic agent how it inhibits IH is not well understood. The objective of this study was to identify modes of action used by R7020 to function in blood vessels that may also contribute to its inhibition of IH. The cytopathic effect of R7020 on SMCs was determined in vitro and in a rabbit IH model. In vitro assays with R7020 infected SMCs were used to quantify the effect of dose on the release kinetics of the virus as well as the effects of R7020 on cell viability and the adhesion of peripheral blood mononuclear cells (PBMCs) to SMCs in the absence and presence of tumor necrosis factor alpha (TNF-α). The observed cytopathic effect, which included R7020 positive filopodia that extend from cell to cell and the formation of syncytia, suggests that R7020 remains cell associated after egress and spreads cell to cell instead of by diffusion through the extracellular fluid. This would allow the virus to rapidly infect vascular cells while evading the immune system. The directionality of the filopodia in vivo suggests that the virus preferentially travels from the media towards the intima targeting SMCs that would lead to IH. The formation of syncytia would inhibit SMC proliferation as incorporated cells are not able to multiply. It was also observed that R7020 induced the fusion of PBMCs with syncytia suggesting the virus may limit the effect of macrophages on IH. Furthermore, R7020 inhibited the proliferative effect of TNF-α, an inflammatory cytokine associated with increased IH. Thus, the results of this study suggest that R7020 inhibits IH through multiple mechanisms.
Highlights
infected cell protein 22 (ICP22) is a multifunctional protein that localizes to the nuclei of infected cells where it regulates several processes involved in Herpes Simplex Virus-1 (HSV-1) replication including nuclear egress [27]
This receptor was expressed on the surfaces of R7020 infected and non-infected smooth muscle cell (SMC) treated with TNF-α but not on the plasma membranes of cells cultured in the absence of TNF-α (Fig 1)
This study suggests that the HSV-1 strain R7020 uses several mechanisms to avoid the immune system and inhibit intimal hyperplasia (IH) in the vasculature
Summary
82.6 million Americans have cardiovascular disease. This includes nearly eight million Americans with peripheral artery disease and 16.3 million Americans with coronary artery disease [1]. Angioplasty, stents and bypass grafts are not ideal solutions for these diseases as they can induce pathological vascular remodeling which results in intimal hyperplasia (IH) and the reoccurrence of symptoms. Intimal hyperplasia [9] is a pathological process that occurs locally in blood vessels. It is a multifaceted disease which includes vascular smooth muscle cell (SMC) proliferation and migration, as well as extracellular matrix production and inflammation [10,11,12,13,14,15]. During the formation of IH SMCs change from a contractile to a synthetic state allowing them to proliferate and synthesize extracellular matrix which are key events in IH formation [16]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.